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iabetic retinopathy is a clinically well-deﬁned,
sight-threatening, chronic microvascular com-
plication that eventually affects virtually all
patients with diabetes. Diabetic retinopathy is
characterized by gradually progressive alterations in the
retinal microvasculature, leading to areas of retinal non-
perfusion, increased vasopermeability, and in response to
retinal nonperfusion, pathologic intraocular proliferation
of retinal vessels (1–3).
Most diabetes researchers and clinicians are aware of
the major advances made in understanding the pathobiol-
ogy of proliferative diabetic retinopathy. However mech-
anisms underlying the progressive alterations in retinal
microvessels, which precede and stimulate neovascular-
ization, are less well-known. In this review, current infor-
mation about the pathogenesis of the primary lesion of
diabetic retinopathy, retinal capillary vasoregression (see
Fig. 1), is presented.
Diabetic retinopathy is often considered as a complica-
tion that contrasts with other vascular sequelae of this
disease because it is associated with new vessel forma-
tion, while diabetic heart disease and diabetic nephropa-
thy are characterized by impaired angiogenesis (4).
Diabetic retinopathy is generally grouped with tumor
angiogenesis and is presented as a paradigm of a neovas-
cular disease (5). As outlined in this review, the natural
history of diabetic retinopathy starts with vasoregression.
Recent investigations have brought new insight regarding
the primary vasoregressive process that stimulates angio-
genesis, provoking new directions of thinking about pos-
sible prevention and intervention (1).
Diabetic retinopathy starts with the loss of the two
cellular components of retinal capillaries: the pericyte, a
vessel support cell, and the endothelial cell. The exact
sequence of loss in humans is not established because
early human retinal samples are not available, but animal
studies have provided evidence that pericytes disappear
before endothelial cells start to vanish, leaving acellular
capillaries with no blood ﬂow (6). In response to progres-
sive retinal capillary dropout, the ischemic retina mounts
an angiogenic response from the surrounding capillaries
leading to proliferative diabetic retinopathy. Correlative
studies of ﬂuorescein angiography and postmortem retinal
digests in humans show that microaneurysms appear to
cluster around areas of acellular capillaries linking struc-
tural damage in situ to clinical markers of disease progres-
sion and suggesting that microaneurysms represent
abortive attempts at neovascularization (7,8).
The mechanism of physiological (sprouting) angio-
genesis. Novel concepts have recently been proposed for
physiological angiogenesis also reﬂecting mechanisms
that might be involved in pathological angiogenesis (9,10).
There are some important molecular players of interest
that dominate both developmental and pathologic retinal
angiogenesis. Under physiological conditions, subsets of
endothelial cells in sprouting vessels qualify for different
functions (Fig. 2). The tip cells guide the vessel along a
gradient of heparin-bound VEGF (vascular endothelial
growth factor)-A (164) sensed by VEGF receptor-2 ex-
pressed on cell extrusions (ﬁlopodia) (11). Tip cells are
incapable of proliferation. In contrast, stalk cells do pro-
liferate. These specialized endothelial cells are prevented
from becoming tip cells by lateral inhibition through the
Notch-Dll system, while their proliferative activity is de-
termined by the availability of VEGF and other growth
factors such as angiopoietin (Ang)-2 (12). The transition
from a proliferating to a mature quiescent endothelial cell,
i.e., the transition from a stalk cell to a so-called phalanx
cell, is determined by the expression of Ang-1 and the ﬁrm
coverage by pericytes, which render these cells resistant
to growth factor depletion by mechanisms that are poorly
understood. On retinal endothelial cells, Tie-2 receptor
activation through Ang-1 binding combines several re-
cruiting signals for smooth muscle cells (and probably
pericytes), including hepatocyte- and heparin-binding
epidermal-like growth factor, but the ﬁrm intramural po-
sitioning of pericytes has yet to be explained. As a novel
ﬁnding, Notch3 is speciﬁcally involved in pericyte recruit-
ment and survival (13).
VEGF and the retina. Previous work using transgenic
mice with isoform-speciﬁc expression of VEGF has indi-
cated that the VEGF-A isoform 164 is the major one
required for proper three-dimensional network formation
in the retina (14). One important contributing factor is the
balance between VEGF’s diffusibility and its heparin-
binding properties. The sole presence of the diffusible
VEGF120 isoform causes severe changes in vessel out-
growth and patterning, pericyte recruitment, and vessel
permeability during early vessel development in the retina.
In contrast, the isolated presence of strongly matrix-
associated VEGF188 impairs arterio-venous differentia-
tion, capillary patterning, and peripheral vascular
outgrowth (15). Another important issue is the relative
abundance of growth factors involved in the development
and maturation of the retinal vasculature. In the nondia-
betic rodent retina, VEGF-A (164) is by far the most
abundant factor expressed, e.g., exceeding that of tumor
necrosis factor- by 30,000-fold. The importance of
VEGF-A for proper retinal vascular development is further
supported by data from mice with conditional inactivation
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depletion of VEGF in nestin-expressing cells are charac-
terized by a sparse capillary network, a smaller capillary
width, 25% fewer endothelial cells, and a sixfold increase
in capillaries devoid of both endothelial cells and peri-
cytes, indicating that VEGF is not only an important
developmental growth factor, but also an important sur-
vival factor (16). When these mice are subjected to the
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FIG. 1. Phenotype of vasoregression in the diabetic retina. In both experimental diabetic rats and diabetic humans, capillary occlusions occur.
Nondiabetic (A) and 6-month diabetic rat retina with acellular capillaries (arrows) (B). Nondiabetic (C) and diabetic (D) human retinal digest
preparation. Periodic acid-Schiff staining (original magniﬁcation 250).
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FIG. 2. Concept of physiological angiogenesis. 1) In tip cells, VEGF stimulates DLL4/NOTCH signaling via VEGF-R2, thereby inhibiting tip cell formation
and inducing VEGF-R1 expression in the endothelial cells downstream. Astrocyte-derived SDF-1 acts as an additional chemoattractant, activating
CXCR4 in tip cells. 2) In stalk cells, predominance of VEGF-R1 and activation of Tie-2 by Ang-2 secreted from the tip cell lead to proliferation and
survival. 3) Platelet-derived growth factor receptor (PDGFR)-–pericytes are attracted to the growing sprout by PDGF-B, released from tip cells.
Interaction of recruited pericytes with endothelial cell–derived Jagged-1 induces the expression of Notch3 and activation of an autoregulatory loop
that further enhances Notch3 activation, thereby promoting pericyte survival, investment, vascular branching, and induction of smooth muscle cell
(SMC) genes. 4) Transforming growth factor (TGF)- produced in endothelial cells further induces SMC differentiation and pericytes-derived Ang-1
binds to and activates the Tie-2 receptor on endothelial cells, thereby stimulating vessel maturation and stabilization.
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reduction in new vessel formation.
In patients with active proliferative diabetic retinopathy,
VEGF levels are increased, while in those eyes in which
proliferative retinopathy is quiescent, VEGF levels are
either normal or only modestly increased (17). Together
these data suggest that VEGF is the most prominent
member of a group of factors that control and facilitate
physiological and pathological angiogenesis.
From a clinical standpoint, the question arises whether
there are certain genetic changes that are associated with
the promotion or the inhibition of retinopathy. In contrast
to many other vascular diseases, diabetic retinopathy in
general has not been found to be strongly and unequivo-
cally linked to genetic defects or polymorphisms. Among
the few signiﬁcantly associated genes are aldose reduc-
tase, the receptor for advanced glycation end products
(RAGE), the integrin 21, and VEGF. From the Diabetes
Control and Complications Trial (DCCT), it is known that
25% of the risk for retinopathy development can be ex-
plained by genetic factors, which are determined by famil-
ial clustering (18). Al-Kateb et al. (19) analyzed the 16
single nucleotide polymorphisms of VEGF in type 1 dia-
betic patients of the DCCT/Epidemiology of Diabetes
Interventions and Complications (EDIC) cohort and tested
the association of these polymorphisms with retinal out-
comes after 10 years during the EDIC study. There was a
strong association of VEGF polymorphisms with the de-
velopment of severe retinopathy but not with retinopathy
progression or diabetic macular edema. Although the
familial clustering suggests a genetic contribution to the
risk of developing advanced lesions, the identity and
function of such contributors are completely unknown.
Apart from genetic factors, epigenetic modiﬁcations in-
duced by hyperglycemia-induced biochemical changes in
the transcriptional machinery of target cells may play a
role that needs to be assessed.
Context-dependent function of the Ang-Tie system.
The Ang-Tie system has received particular attention as a
key regulator of adult vascular homeostasis (20–23). The
receptor tyrosine kinase Tie-2 is expressed on endothelial
cells, regulating vascular remodeling and maturation. The
balance between the two ligands Ang-1 and -2 determines
the phosphorylation status of Tie-2, thereby regulating
endothelial barrier function, vessel branching, inﬂamma-
tory responses, and angiogenesis (24–26). Ang-1 is consid-
ered to be an activator of Tie-2, while Ang-2 is a
homologous ligand that antagonizes Ang-1 activity on
Tie-2, acting as an endogenous dominant negative ligand
for Ang-1. During developmental angiogenesis, Ang-1 ex-
pression appears to be the initial step of vessel maturation,
causing endothelial cell differentiation and recruitment of
pericyte precursors, which stabilize the new vessels
(22,27). Transforming growth factor-1 further contributes
to the ﬁnal maturation steps by downregulation of cell
migration and promotion of cell differentiation. Adult
vessel remodeling involves the interplay between VEGF
and the ratio of Ang-1 and -2. When the ratio of Ang-2 to
Ang-1 is high and VEGF is high in hypoxic tissues, the
consequence is sprouting angiogenesis. In contrast, in the
absence of VEGF, Ang-2 upregulation leads to vasoregres-
sion. Isolated downregulation or the absence of Ang-1
causes vessel destabilization through effects on pericytes
(27).
Hyperglycemia and the molecular changes in the
early diabetic retina. The most relevant morphological
lesion in the diabetic retina is the acellular, nonperfused
capillary segment (1). It reﬂects the net result of multiple
damaging mechanisms involving endothelial, matrix, peri-
cyte, and microenvironmental components. Thus retinop-
athy does not deviate from all the other vascular
phenotypes in diabetes as is often thought. Diabetic reti-
nopathy is part of a systemic vascular disease in which
vasoregression is the primary evolutionary process. Va-
soregression in the diabetic retina starts with pericyte
loss. This is a long-known feature, and it has been consis-
tently reported in diabetic animals and humans (2,6). As
noted above and elaborated upon in a recent review by
Betsholtz and colleagues (28), ligand-receptor systems
involved in endothelial-pericyte (mural) cell signaling de-
termine the fate of pericytes not only during vascular
development, but also during incipient diabetic retinopa-
thy (18). The concept, proposed by Hanahan, is that Ang-2
overexpression in cooperation with VEGF overexpression
leads to pericyte loss and angiogenesis, while Ang-2 over-
expression in the absence of VEGF leads to vasoregres-
sion (25). Figure 3 summarizes the context-dependent
expression and regulation of the Ang-Tie system with the
focus on diabetic vasoregression and angiogenesis. When
determined in an experimental diabetic rat model in which
pericyte dropout was precisely ascertained, Ang-2 upregu-
lation (37-fold) preceded the onset of pericyte dropout (6).
In young nondiabetic rats, pericyte dropout was inducible
by intravitreal injection of recombinant Ang-2. Moreover
in heterozygous diabetic Ang-2 knockout mice, pericyte
dropout was prevented, and in mice with constitutive
retinal overexpression of Ang-2, pericyte dropout was
exaggerated. Together these data suggest that Ang-2 is
involved in the pathogenesis of diabetic pericyte loss.
Ang-2 upregulation by hypoxia is an established fact.
However the early diabetic (rodent) retina is not hypoxic.
Therefore hyperglycemia-induced regulation of Ang-2 was
investigated. Hyperglycemia-induced mitochondrial over-
production of reactive oxygen species has been shown to
induce altered gene transcription by covalent modiﬁcation
of coregulatory proteins. In renal endothelial cells, it was
found that a complex consisting of the transcriptional
co-repressor mSin3A and the transcription factor Sp3
suppresses transcriptional activity by binding to a glucose-
sensitive GC box in the Ang-2 promoter. Hyperglycemia-
induced formation of methylglyoxal modiﬁes mSin3A
resulting in increased recruitment of O-GlcNAc trans-
ferase to an mSin3A-Sp3 complex and a subsequent
increased modiﬁcation of Sp3 by O-linked N-acetylglu-
cosamine. Gluc-NAc modiﬁcation of Sp3 causes decreased
binding of the repressor complex to the glucose-respon-
sive GC box in the Ang-2 promoter resulting in increased
Ang-2 expression (27) (Fig. 4).
Pericyte migration: a novel mechanism of diabetic
pericyte loss. Data from human and animal studies have
suggested that diabetic pericyte loss is the result of
apoptosis induced by activation of nuclear factor-B (NF-
B) or, as has been recently pointed out, by activation of
the protein tyrosine phosphatase SHP-1 in an NF-B
independent pathway. Apoptosis is determined by a tran-
sient indicator (e.g., nuclear fragmentation). Still, the
number of lost pericytes from apoptotic pericytes ob-
served in retinal digest specimens is lower than the
projected number of pericytes lost in total after several
months of diabetes, suggesting that additional mecha-
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tal origin and the morphological diversity of pericytes in
retinal capillaries suggest that not all pericytes are alike.
Pﬁster et al. (31) used quantitative retinal morphology and
normal and diabetic mice with different levels of Ang-2
expression to study which pericytes were lost in the
diabetic retina and whether it was due to changes in Ang-2.
The investigators categorized pericytes into three classes:
1) located at vessel branches (saddle pericytes), 2) located
on straight parts of capillaries, and 3) showing different
degrees of detachment from adjacent endothelial cells
(migrating pericytes) (Fig. 5). The investigators found that
saddle pericytes remained unaffected by diabetes while
only pericytes on straight parts of capillaries were reduced
in diabetic retinae in parallel with an increased number of
migrating pericytes. In nondiabetic Ang-2–overexpressing
animals, this number was increased by 78%, while in
Ang-2–deﬁcient mice, the numbers of migrating pericytes
was reduced by 36% (31). Together, these data favor
pericyte migration as an important mechanism for diabetic
pericyte loss.
The fate of migrating pericytes in the diabetic retina
remains uncertain, but inferential evidence from work on
brain pericytes suggests that they migrate away from an
injured capillary for survival (32). As noted in the trau-
matic brain injury model, stress-induced migration of
pericytes resulted in their survival. Pericytes that stayed at
their vessel location and did not migrate were prone to
apoptosis, suggesting that migration of pericytes away
from the capillary enables the pericyte to respond to
trophic signaling molecules in the perivascular compart-
ment. The subsequent functional adaptations may include
differentiation along multiple lineages reﬂecting the pluri-
potency of this enigmatic cell population (33).
After regional hypoxia occurs in the diabetic retina as a
result of vasoregression and capillary dropout, retinal
neovascularization occurs in an attempt to restore oxygen
delivery. Both VEGF and Ang-2 are normally induced by
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FIG. 3. In the mature vasculature, pericyte-derived Ang-1 dominates Ang-2, leading to Tie-2 phosphorylation in endothelial cells. Activation of
Tie-2 controls endothelial cell proliferation and induces intercellular contacts and junctions, thereby stabilizing retinal vasculature and
promoting the formation of the blood-retinal barrier (A). Diabetes-induced vasoregression is a result of Ang-2 upregulation in the absence of
hypoxia. Retinal endothelial cells and glial cells (Mu ¨ller cells) express Ang-2 as a dominant negative ligand blocking Tie-2 phosphorylation.
Upregulation of Ang-2 induces vascular cell depletion and progressive capillary occlusion (B). Growing areas of nonperfusion lead to
upregulation of hypoxia-induced factors such as VEGF and Ang-2. In pericytes, Notch3 activation under hypoxic conditions induces Ang-2
expression. Abundance of VEGF without a succinct gradient and elevated Ang-2 levels destabilize vessels, cause endothelial cell proliferation and
pericyte activation. Bone marrow–derived progenitor cells contribute to pathological angiogenesis (C). P, phosphate. (A high-quality color
representation of this ﬁgure is available in the online issue.)
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Feng et al. (36), using homozygous Ang-2–deﬁcient mice,
reported spontaneous proliferative retinopathy occurring
in room air that mimicked human retinopathy of prema-
turity (ROP) in mice. Arteriolar patterning and the forma-
tion of the primary (superﬁcial) and secondary (deep)
capillary network were impaired due to the lack of Ang-2.
Over time, the relative increase of VEGF in this model
declined, rendering persistent preretinal proliferations
less leaky. Reduced matrix metalloproteinase (MMP) ac-
tivity, which is evident in heterozygous Ang-2–deﬁcient
mice causing a reduction in proliferative retinopathy, may
be overcome by VEGF-induced MMP regulation in the
complete absence of Ang-2. Thus, Ang-2 appears negligible
for retinal neovascularization, but it is essential for proper
vessel development, in particular of the arteriolar site, and
the capillaries in the depth of the retina where diabetic
retinopathy starts.
Erythropoietin in the diabetic retina. Erythropoietin
(Epo) is another ischemia-induced growth factor that was
recently identiﬁed as being important in the pathogenesis
of proliferative diabetic retinopathy. Work by Takagi and
colleagues (37) demonstrated that Epo is increased in eyes
with proliferative diabetic retinopathy, and the experimen-
tal inhibition of Epo is as effective as that of VEGF in the
ROP model. More recently, a large consortium (38) re-
ported that promoter polymorphisms of the Epo gene are
associated with proliferative diabetic retinopathy in pa-
tients, with increased promoter activity giving rise to
increased Epo transcription. Critically, the effect of exog-
enous Epo depends on the temporal relation to the induc-
tion of vasoregression (39). In the ROP model, Epo
administered prior to the induction of vasoregression (i.e.,
before mice went into the hyperoxic chamber) reduced
vasoregression and, consequently, responsive neovascu-
larization, while Epo, administered after vasoregression
had occurred, induced increased neovascularization. The
effect of Epo is mediated by a complex consisting of the
Epo receptor, which is expressed throughout the entire
retina, and the common chain receptor, which is ex-
pressed only in the vicinity of the superﬁcial vascular
layer, i.e., in the layer in which most neovascularizations
develop. Low-dose Epo, which does not induce erythro-
poiesis over a period of up to 6 months, inhibited oxidative
stress in the retinae of STZ-diabetic rats and reduced
VEGF and Ang-2 levels (40). The formation of acellular
capillaries and the loss of pericytes were also reduced in
these Epo-treated diabetic animals. The formation of acel-
lular capillaries and the loss of pericytes were reduced in
treated diabetic animals. Of particular note, the increased
level of leukostasis (i.e., local capillary obstruction by
leukocytes [see below]) remained unaffected by Epo treat-
ment (Q. Wang et al., unpublished data), suggesting that
leukostasis does not play a major role in causing vasore-
gression in the diabetic retina.
Factors modulating vasoregression
Inﬂammation. Inﬂammation is an important pathoge-
netic aspect of diabetic retinopathy based on the ﬁndings
that inﬂammatory cytokines and mediators are upregu-
lated in the diabetic retina, and that leukostasis occurs
because of adhesion molecule upregulation (41–45). As a
novel aspect, microglial cells transdifferentiating from
bone marow–derived cells may contribute to the propaga-
tion of inﬂammatory vessel damage. This area has been
the subject of two recent exciting reviews (46,47) address-
ing the multifaceted and important link between inﬂam-
mation and diabetic retinal vasoregression.
Leukostasis. Since the early reports by Schmidt-Scho ¨n-
bein, leukostasis has evolved as a mechanism by which
activated bone marrow–derived cells may damage retinal
capillary endothelial cells (44,48). It was noted that leuko-
cytes adhered to the diabetic endothelium in all vascular
beds of the retina, and some leukocytes obstruct capillar-
ies. Several studies implied that correction of leukostasis
necessarily preserved retinal capillaries from occlusion
(49–51). However, as outlined above, new experimental
evidence suggests that the prevention of acellular capillar-
ies succeeds without correction of leukostasis (42,52) (Q.
Wang et al., unpublished data).
Endothelial progenitor cells. Another bone marrow–
derived cell population that is able to interact with the
endothelium in damaged tissues is the endothelial progen-
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FIG. 4. Mechanism of hyperglycemia-induced Ang-2 regulation. A: Under physiological (normoglycemic) conditions, a transcriptional complex
(involving the transcriptional corepressor mSin3A) represses Ang-2 transcription by binding to a glucose-sensitive GC box. B: Transcriptional
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have attracted much interest because of their potential
role in vascular repair. From studies using models of
proliferative retinopathy, the contribution of hematopoi-
etic stem cells to retinal neovascularization has been
proposed (53). In this context, the chemokine SDF-1 was
established as an important promoter of adult retinal
angiogenesis in a model of laser-induced retinal vein
occlusion (54). Blocking SDF-1 activity abolished the
recruitment of hematopoietic stem cell–derived endothe-
lial precursors and local endothelial cell–driven ischemic
repair, preventing preretinal neovascularization.
The question of whether EPCs can support the repair of
damaged endothelial cells was also addressed in experi-
mental studies. Using rodent models in which capillary
endothelial cells were damaged by different mechanisms,
Caballero et al. (55) used labeled CD34 cells from both
nondiabetic and diabetic origin and found that only non-
diabetic cells were able to integrate into the damaged
vasculature. EPCs, which have impaired function, may be
restored by improvements in mobilization, e.g., by statins,
or by drugs that improve function, adding to the self-repair
of damaged capillaries in the diabetic retina.
Apart from being expressed on endothelial cells, Tie-2 is
expressed on bone marrow–derived monocytes/macro-
phages (TEM), and the interaction with local tissue Ang-2
(such as in hypoxic tumor areas) promotes angiogenesis
(56). High Ang-2 in the diabetic retina may cause a
recruiting signal for TEM and direct them to the retina.
The relevance of this pathway and the possible role in
vasoregression await clariﬁcation.
Lipids and fatty acids. Vasoregression in the diabetic
retina may also result from hyperglycemia-induced modi-
ﬁcations of the levels or the chemical make-up of lipids
and fatty acid–based lipid mediators, as suggested by
clinical and experimental studies such as the DCCT and
others (57–59). Two distinct entities of modiﬁcations have
been proposed: 1) posttranslational modiﬁcation of li-
poproteins and 2) diabetes-induced alterations in the
biosynthesis of eicosanoids. Examples for modiﬁed li-
poproteins as possible mediators of retinal vessel toxicity
have been given by Lyons and colleagues (60). They
showed that oxidized LDL is toxic for pericyte and can
contribute to pericyte death. Diabetes-induced changes in
proinﬂammatory eicosanoids are derived from arachi-
donic acid, and anti-inﬂammatory resolvins and protectins
are derived from -3 polyunsaturated fatty acids. In the
diabetic retina, elongase and desaturase proﬁles are sub-
stantially altered leading to a decrease in these -3 unsat-
urated fatty acids (61). As they can affect retinal gene
expression with subsequent changes in cell differentiation
and survival, diabetes-induced reductions in -3 PUFAs
and increases in arachidonic acid can contribute to both
vasoregression and neovascularization because of the lack
in antiproliferative and proinﬂammatory effects. In addi-
tion to their proinﬂammatory effects, eicosanoids can
increase Ang-2 expression either directly or via the modi-
ﬁcation of VEGF expression (62).
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FIG. 5. Schematic illustration linking hyperglycemia-induced reactive
oxygen species (ROS) overproduction with Ang-2–dependent vasore-
gression and combined ischemia/hypoxia-induced angiogenesis. In
healthy retinal capillaries, proper pericyte coverage ensures endothe-
lial cell survival and integrity of blood-retinal barrier by Ang-1/Tie-2
signaling. Chronic hyperglycemia induces cell damage and upregulation
of Ang-2 in retinal endothelial cells and Mu ¨ller cells (MC), leading
to retinal pericyte detachment, migration, apoptosis, and progressive
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fused, leading to the upregulation of survival/growth factors such as
VEGF. During the later stages, which is not represented in rodent
models, increased expression of hypoxia-induced VEGF and increased
Ang-2 levels lead to preretinal neovascularization. HXP, hexosamine
pathway; EC, endothelial cell. (A high-quality color representation of
this ﬁgure is available in the online issue.)
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retinopathy familiar to clinical diabetologists is not the
primary pathogenic response of the retina to chronic
hyperglycemia. Rather, it is an attempted compensation
for retinal hypoxia caused by loss of capillary pericytes
and followed by formation of acellular, nonperfused cap-
illaries. This vasoregression is the primary pathogenic
response of the retina to chronic hyperglycemia. Central
mediators of pericyte loss and acellular capillary forma-
tion include hyperglycemia-induced alterations in levels of
VEGF isoforms, Ang-1 and -2; recruitment of activated
macrophages, microglia, and/or leukocytes from the bone
marrow; increased proinﬂammatory eicosanoid produc-
tion; and decreased anti-inﬂammatory resolvins and pro-
tectins derived from -3 polyunsaturated fatty acids. Many
of these changes are mediated by consequences of hyper-
glycemia-induced reactive oxygen species. Further eluci-
dation of the mechanisms by which chronic hyperglycemia
causes intraretinal vasoregression (Fig. 6) will provide
new targets for pharmaceutical intervention before irre-
versible retinal ischemia and secondary proliferative reti-
nopathy necessitate damaging treatments such as
panretinal laser photocoagulation.
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